Patent US4565789A successfully refreshed from Google Patents.
US4565789A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Cell matrix receptor system and use in cancer diagnosis and management
Assignee: United States Department of Health and Human Services
•
Filing: 1983-04-04
•
Granted: 1986-01-21
•
Expires: 2003-04-04
Abstract
Abstract A cell matrix receptor specific for laminin expressed on the surface of carcinoma and epithelial cells is provided. The binding of these cells to extracellular matrix is mediated by the laminin molecule, which has binding domains for type IV collagen of the matrix and the cell surface receptor. Fragments of the laminin molecule lacking the type IV collagen binding domain and antibodies to the receptor are useful in conjunction with the cell receptor as ligands in binding assays for cancer diagnosis and in cancer management.
Inventors
- 👤 Lance A. Liotta
- 👤 Nageswara C. Rao
- 👤 Victor Terranova
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:31
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/575; G01N33/5751; A; A61; A61P; A61P35/00; G01N33/5758; G01N2333/00; G01N2333/435; G01N2333/705; G01N2333/78; Y; Y10; Y10S; Y10S436/00; Y10S436/807; Y10S436/808; Y10S436/811; Y10S436/813
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
9 words
An isolated receptor having specific binding affinity for laminin.
Claim 2
Dependent Claim
9 words
An isolated receptor having specific binding affinity for laminin.
Claim 3
Dependent Claim
18 words
The receptor of claim 1 being purified and having a molecular weight of about 50,000 to about 75,000.
Claim 4
Dependent Claim
44 words
A method for evaluating the effectiveness of a chemotherapeutic agent for treating cancer cells expressing the receptor of claim 1, comprising interacting a conjugate of the agent and a ligand specific for said receptor with a population of carcinoma cells prior and after chemotherapy.
Claim 5
Dependent Claim
22 words
A laminin fragment having a binding domain for the receptor of claim 1 without having a binding domain for type IV collagen.
Claim 6
Dependent Claim
27 words
The receptor of claim 1 complexed with a ligand comprising laminin, a laminin fragment having a binding domain for the receptor, or an antibody to the receptor.
Claim 7
Dependent Claim
59 words
A method for inhibiting attachment to type IV collagen of cells having the receptor of claim 1 comprising blocking the receptor site of said cells with a laminin, a laminin fragment having a binding domain for the cell receptor without having a binding domain for type IV collagen, a ligand having specificity against said receptor, or an analogue thereof.
Claim 8
Dependent Claim
13 words
The method of claim 6, wherein the cells are human breast carcinoma cells.
Claim 9
Dependent Claim
43 words
A method for separating metastatic cancer cells expressing the cell receptor of claim 1 from a mixed population of cells comprising binding the metastatic cancer cells to a ligand having a binding domain for the cell receptor, and separating bound from unbound cells.
Claim 10
Dependent Claim
23 words
The method of claim 8, wherein the ligand is laminin or a laminin fragment obtained by digestion of laminin with a proteolytic enzyme.
Claim 11
Dependent Claim
10 words
An antibody being specifically reactive to receptor of claim 1.
Claim 12
Dependent Claim
36 words
A method for detecting the presence of human breast carcinoma comprising reacting a sample of a tissue suspected to have said carcinoma with antibody of claim 10 and determining binding between said tissue and the antibody.
Claim 13
Dependent Claim
13 words
The method of claim 11 wherein said sample is a plasma membrane fraction.
Claim 14
Dependent Claim
15 words
The method of claim 12 determining said binding by radioimmunoassay wherein said antibody is radiolabelled.
Claim 15
Dependent Claim
38 words
A method for localizing a chemotherapeutic agent on the surface of cancer cells expressing the receptor of claim 1, comprising conjugating the agent with a ligand specific for the cell receptor, and interacting the conjugate with said cells.
Claim 16
Dependent Claim
14 words
The method of claim 14, wherein the ligand is an antibody for the receptor.
Claim 17
Dependent Claim
14 words
The method of claim 14, wherein the cancer cells are human breast carcinoma cells.
Claim 18
Dependent Claim
21 words
The method of claim 14, wherein the ligand is laminin or a laminin fragment having a binding domain for said receptor.
Claim 19
Dependent Claim
32 words
A therapeutic composition of inhibiting growth of carcinoma cells having the receptor of claim 1, comprising a pharmaceutically acceptable carrier and growth inhibiting amount of a ligand having specificity against said cells.
Claim 20
Dependent Claim
28 words
The therapeutic composition of claim 18, wherein said ligand is selected from the group consisting of laminin, a laminin fragment and an antibody having specificity against said receptor.
Claim 21
Dependent Claim
18 words
The therapeutic composition of claim 18, wherein the laminin fragment lacks a binding domain for type IV collagen.
Claim 22
Dependent Claim
18 words
The therapeutic composition of claim 18, wherein the laminin fragment includes a binding domain for type IV collagen.
Claim 23
Dependent Claim
48 words
A kit for detecting the presence of metastasizing cancer cells having the receptor of claim 1, comprising a container containing a ligand selected from the group consisting of laminin, a laminin fragment having a binding domain for the cell receptor and an antibody having specificity for the receptor.
Claim 24
Dependent Claim
22 words
The diagnostic kit of claim 22, wherein the laminin fragment is the digestion product of laminin and chymotrypsin, cathepsin G, or plasmin.
Claim 25
Dependent Claim
10 words
The kit of claim 22, wherein the ligand is radiolabelled.
Claim 26
Dependent Claim
25 words
The kit of claim 24 wherein the kit further comprises an unlabelled ligand which competes with the labelled ligand for binding to the cell receptor.
Claim 27
Dependent Claim
16 words
The kit of claim 24 wherein the labelled ligand is an antibody to the cell receptor.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-01-20 | 1989-07-22 | 1990-01-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-01-20 | 1993-07-22 | 1994-01-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-01-20 | 1997-07-22 | 1998-01-21 | $7700.00 | Window Closed / Lapsed |